Latest Conference Articles

October 21st 2018, 12:01am

ESMO Congress

The combination of palbociclib plus fulvestrant led to a clinically meaningful benefit in overall survival in patients with hormone receptor–positive, HER2-negative advanced breast cancer who had progressed or relapsed on prior endocrine therapy.

October 20th 2018, 9:35pm

ESMO Congress

Distinct gene signatures in renal cell carcinoma correlated with improved progression-free survival with immunotherapy or a targeted agent, according to a new analysis of the phase III IMmotion151 trial.

October 20th 2018, 8:40pm

ESMO Congress

Massimo Cristofanilli, MD, professor of medicine (hematology and oncology), Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses survival findings from the PALOMA-3 trial in hormone receptor-positive, HER2-negative breast cancer.

October 20th 2018, 7:04pm

ESMO Congress

The addition of atezolizumab to nab-paclitaxel reduced the risk of progression or death by 38% compared with nab-paclitaxel alone in patients with PD-L1–positive metastatic triple-negative breast cancer.

October 20th 2018, 1:10pm

ESMO Congress

Jonathan E. Rosenberg, MD, medical oncologist, chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses dosing for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with metastatic urothelial carcinoma at the 2018 ESMO Congress.

October 20th 2018, 3:39am

ESMO Congress

Adding radium-223 dichloride to abiraterone acetate and prednisone did not improve survival in patients with metastatic castration-resistant prostate cancer.

October 20th 2018, 12:18am

State of the Science Summit on Hematologic Malignancies

Ravi Vij, MD, MBA, professor of medicine, Division of Oncology, Section of Bone Marrow Transplant, Washington University School of Medicine, Siteman Cancer Center, discusses the optimal induction therapy in the treatment of patients with multiple myeloma.

October 20th 2018, 12:16am

State of the Science Summit on Hematologic Malignancies

Stephen Oh, MD, PhD, assistant professor of medicine, Division of Hematology, Washington University School of Medicine, Siteman Cancer Center, discusses the development of JAK inhibitors in myelofibrosis.

October 19th 2018, 11:27pm

ESMO Congress

MET amplification and EGFR C797S mutations are the most commonly observed alterations associated with resistance to first-line osimertinib in patients with EGFR-mutant non–small cell lung cancer.

October 19th 2018, 6:00am

State of the Science Summit on Hematologic Malignancies

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses the use of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL).

October 18th 2018, 12:09am

State of the Science Summit on GI Malignancies

Anthony B. El-Khoueiry, MD, discusses the promising hepatocellular carcinoma treatment paradigm.

October 17th 2018, 10:19pm

State of the Science Summit on GI Malignancies

Afsaneh Barzi, MD, discusses updates in the treatment of patients with pancreatic cancer, as well as the importance of genetic testing.

October 17th 2018, 9:46pm

State of the Science Summit on GI Malignancies

Heinz-Josef Lenz, MD, discusses the intersection between the molecular makeup of colorectal cancer and the development of novel therapies in the treatment paradigm.

October 17th 2018, 1:36am

State of the Science Summit on GI Malignancies

Anthony El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses recent combination data in hepatocellular carcinoma.

October 17th 2018, 12:34am

State of the Science Summit on GI Malignancies

Syma Iqbal, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses treatment options for patients with neuroendocrine tumors (NETs).

October 16th 2018, 10:00am

State of the Science Summit on GI Malignancies

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the FDA breakthrough designation status of encorafenib (Braftovi), binimetinib (Mektovi), and cetuximab (Erbitux) for the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer (CRC).

October 16th 2018, 12:24am

State of the Science Summit on GI Malignancies

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses the changing landscape of metastatic colorectal cancer (mCRC).

October 14th 2018, 11:32pm

Lynn Sage Breast Cancer Symposium

Massimo Cristofanilli, MD, discusses a session at the 20th Annual Lynn Sage Breast Cancer Symposium on the roles of a multidisciplinary team.

October 14th 2018, 11:30pm

Lynn Sage Breast Cancer Symposium

George Sledge, Jr., MD, discusses the benefit to the cost of genomic sequencing decreasing overtime.

October 14th 2018, 9:34pm

Lynn Sage Breast Cancer Symposium

As the cost of sequencing continues to fall, genomic testing will likely become widespread in all types of metastatic cancer, including breast cancer.